Loading clinical trials...
Loading clinical trials...
A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
Conditions
Interventions
CYC065
Locations
1
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
September 28, 2015
Primary Completion Date
October 4, 2022
Completion Date
August 25, 2023
Last Updated
May 31, 2024
NCT05884320
NCT05692635
NCT05702398
NCT05673200
NCT05691465
NCT06498635
Lead Sponsor
Cyclacel Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions